Policies, procedures and guidelines

Approved policies, procedures and guidelines

• MU IBC Charter (revised 1-19-2023)
• MU IBC guidance for working with SARS-CoV-2 (adopted 6-17-2025)
• MU IBC policy statement on toxins of biological origin (revised 8-13-2013)
• MU IBC policy statement on human/nonhuman primate cell lines (revised 8-17-2023)
• MU IBC policy statement on transgenic animals (revised 9-21-2023)
• MU IBC core facility guidelines (revised 8-15-2024)
• MU IBC policy statement on transgenic plants (revised 5-18-2023)
• MU IBC policy on handling lentivirus, adenovirus and AAV-based vectors (revised 04-26-2023)
• MU IBC human gene transfer trials serious adverse event reporting policy (adopted 11-21-2013)
• MU IBC policy on IBC meeting minutes (revised 10-19-2023)
• MU IBC policy on redacting IBC meeting minutes (adopted 2-16-2024)
• MU IBC policy on receipt and transmission of public comments (adopted 2-16-2024)
• MU IBC conflict of interest policy (revised 6-19-2024)
• MU IBC dual use research of concern (DURC) (adopted 9-17-2015)
• MU IBC policy on renewals, suspensions and terminations of protocols (revised 8-18-2022)
• MU vaccination policy and surveillance guidelines (login required; approved by IBC 3-17-2022)